News Center
The major "12th Five-Year Plan" project on innovative drug development successfully concluded.
Release date:
2018-06-01
The New Drug Special Project is a science and technology initiative focused on developing critical national strategic products and achieving significant industrialization goals through integrated, collaborative research efforts within a set timeframe. Implemented from 2008 to 2020, the project follows a phased approach guided by a development strategy outlined in three five-year plans—“Lay the Foundation,” “Organize Resources,” and “Make Breakthroughs”—to systematically advance its objectives. The overarching goal of the New Drug Special Project is to independently develop and technologically upgrade a range of drugs targeting 10 major diseases, including malignant tumors, while simultaneously strengthening the nation’s drug innovation ecosystem. This initiative aims to enhance China’s core R&D capabilities, accelerate the growth of the pharmaceutical industry, and ultimately drive a transformative shift—from generic drug production toward innovative drug development—and propel the industry from a global manufacturing powerhouse to a true leader in the global pharmaceutical sector.
In 2012, Shengshi Taikang independently undertook the nation’s major “12th Five-Year Plan” project for new drug development—despite starting with a tiny team of just 11 people. Thanks to the collective efforts of everyone at the company, we successfully met and even exceeded our ambitious goals, earning high praise from the review experts and achieving a flawless project completion. The initiative also resulted in two authorized patents and one clinical trial approval. Notably, Shengshi Taikang’s founder and CEO, Yu Qiang, who served as the project leader, was subsequently selected for the prestigious National Thousand Talents Program. Currently, the innovative new diabetes drug, Shengeteglitin, has smoothly advanced into the clinical phase, delivering promising results. Meanwhile, the project continues to receive robust support from the nation’s “13th Five-Year Plan” major initiatives—and is now spearheaded by Ding Juping, Co-founder and Chairman of Shengshi Taikang, alongside CEO Yu Qiang. 
Project (Research Topic) Task Acceptance Review:
This project has successfully exceeded its target milestones, leading to the development of a novel antidiabetic drug—phosphate sengliflozin—with a proprietary dipeptidyl peptidase-targeting mechanism. The compound has already secured the relevant clinical approval and two patent authorizations. As a Class I chemical new drug candidate, it demonstrates strong innovation and independent intellectual property rights, positioning it as a promising therapeutic option. The project leader has been selected for the Thousand Talents Program, underscoring the team's remarkable achievements in talent development. With the project surpassing its objectives and securing both clinical approval for the Class I chemical drug and two patent licenses, we recommend that the project be officially approved and closed.
Contact Information
Address: Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123
Tel： +86-512-62956960（Recruitment）
+86-512-62956961（marketing）
Copyright © 2022 CGeneTech (Suzhou, China) Co., Ltd.
在线客服添加返回顶部
页面顺滑的滚动
屏蔽页面上图片的alt/title提示
右侧在线客服样式 1,2,3 2
图片alt标题设置： Fland Environmental
表单验证提示文本： The content cannot be empty!
循环体没有内容时： Content is being organized—please wait!
CSS / JS 文件放置地